Skip to main content
Top
Published in: International Journal of Hematology 3/2013

01-03-2013 | Images in Hematology

Hypopyon as the first sign of relapse in acute lymphoblastic leukaemia

Authors: Daniela Barraco, Anna Candoni, Erica Simeone, Angelo Pirracchio, Renato Fanin

Published in: International Journal of Hematology | Issue 3/2013

Login to get access

Excerpt

Ocular localizations ranging from leukemic retinopathy to involvement of the iris and anterior chamber may be observed as clinical manifestations of acute lymphoblastic leukaemia (ALL). Involvement of the anterior ocular segment is very rare in adult ALL, and is found in less than 1 % of leukaemic relapses [1, 2]. We report a case of leukemic hypopyon, secondary to sedimentation of leukemic blast cells in the ocular anterior chamber, occurring in a 62-year-old woman with T-ALL who was treated with the induction chemotherapy including methotrexate, cytarabine, cyclophosphamide, doxorubicin, vincristine, and dexamethasone, also with a central nervous system (CNS) prophylaxis, and achieved a complete remission. Fourteen months after the first complete remission, while receiving maintenance therapy (mercaptopurine and methotrexate), the patient complained of an ipsilateral reduction of visual acuity on the left associated with changes in head position. Ophthalmic evaluation was performed, showing a leukemic hypopyon with a horizontal fluid level (measuring 3 mm) in the left eye. The patient refused anterior chamber paracentesis. A lumbar puncture revealed CNS relapse with 50 blast cells/μL of cerebrospinal fluid (CSF). The lymphoid blasts were positive for CD7, CD5, CD2, and CD13. Although the patient was treated with intrathecal chemotherapy with methotrexate and cytarabine, and later with liposomal cytarabine, with a clearing of malignant cells from the CSF, a worsening of the anterior chamber hypopyon was noted and the patient required ocular radiotherapy with a transient and partial response. The patient died (7 months after the diagnosis of hypopyon) with ocular, cutaneous, and bone marrow leukemic involvement. …
Literature
1.
go back to reference Yi DH, Rashid S, Cibas ES, Arrigg PG, Dana MR. Acute unilateral leukemic hypopyon in an adult with relapsing acute lymphoblastic leukemia. Am J Ophthalmol. 2005;139:719–21.PubMedCrossRef Yi DH, Rashid S, Cibas ES, Arrigg PG, Dana MR. Acute unilateral leukemic hypopyon in an adult with relapsing acute lymphoblastic leukemia. Am J Ophthalmol. 2005;139:719–21.PubMedCrossRef
2.
go back to reference Wetzler M. Unusual manifestations of acute leukemia. Case 3. Unilateral leukemic hypopyon. J Clin Oncol. 2000;18(19):3439–40.PubMed Wetzler M. Unusual manifestations of acute leukemia. Case 3. Unilateral leukemic hypopyon. J Clin Oncol. 2000;18(19):3439–40.PubMed
Metadata
Title
Hypopyon as the first sign of relapse in acute lymphoblastic leukaemia
Authors
Daniela Barraco
Anna Candoni
Erica Simeone
Angelo Pirracchio
Renato Fanin
Publication date
01-03-2013
Publisher
Springer Japan
Published in
International Journal of Hematology / Issue 3/2013
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-013-1283-2

Other articles of this Issue 3/2013

International Journal of Hematology 3/2013 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine